Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 7/20 | 0.65 |
| ▸ | TNF | P01375 | 3/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.63 |
| ▸ | LMNA | P02545 | 2/20 | 0.63 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | PDE4A | P27815 | 1/20 | 0.56 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.56 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.56 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11321532 | 0.93 | TNF (0.66) | ADORA2BTNFSMN1; SMN2LMNARXFP1 | |
| SCHEMBL12260494 | 0.88 | SMN1; SMN2 (0.76) | ADORA2BSMN1; SMN2LMNARXFP1MAPK1 | |
| SCHEMBL24559132 | 0.88 | TNF (0.59) | ADORA2BTNFSMN1; SMN2LMNARXFP1 | |
| SCHEMBL3860920 | 0.87 | SMN1; SMN2 (0.78) | ADORA2BSMN1; SMN2LMNARXFP1MAPK1 | |
| SCHEMBL27880859 | 0.85 | ADORA2B (0.73) | ADORA2BSMN1; SMN2LMNARXFP1MAPK1 | |
| SCHEMBL11382208 | 0.84 | SMN1; SMN2 (0.62) | ADORA2BSMN1; SMN2LMNARXFP1MAPK1 | |
| SCHEMBL6743410 | 0.83 | ADORA2B (0.66) | ADORA2BSMN1; SMN2LMNARXFP1MAPK1 | |
| SCHEMBL9296212 | 0.82 | ADORA2B (0.76) | ADORA2BSMN1; SMN2LMNARXFP1MAPK1 | |
| SCHEMBL10967382 | 0.82 | MAPK1 (0.82) | ADORA2BSMN1; SMN2LMNARXFP1MAPK1 | |
| SCHEMBL11379379 | 0.82 | ADORA2B (0.62) | ADORA2BSMN1; SMN2LMNARXFP1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12559495-B2 | Purine diones as Wnt pathway modulators | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2026-02-24 | — | — | US | disclosed |
| US-20230174533-A1 | PURINE DIONES AS WNT PATHWAY MODULATORS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2023-06-08 | — | — | US | disclosed |
| US-20230174533-A1 | PURINE DIONES AS WNT PATHWAY MODULATORS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2023-06-08 | — | — | US | disclosed |
| US-20230174533-A1 | PURINE DIONES AS WNT PATHWAY MODULATORS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2023-06-08 | — | — | US | disclosed |
| US-11555037-B2 | Purine diones as Wnt pathway modulators | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2023-01-17 | — | — | US | disclosed |
| US-20220202821-A1 | SMALL MOLECULE PARG INHIBITORS AND METHODS OF USE THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-06-30 | — | — | US | disclosed |
| CN-109776537-B | Purine diones as WNT pathway modulators | 新加坡科技研究局 | 2021-12-14 | — | — | CN | disclosed |
| US-20210155623-A1 | PURINE DIONES AS WNT PATHWAY MODULATORS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2021-05-27 | — | — | US | disclosed |
| US-20210155623-A1 | PURINE DIONES AS WNT PATHWAY MODULATORS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2021-05-27 | — | — | US | disclosed |
| US-10844063-B2 | Purine diones as Wnt pathway modulators | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2020-11-24 | — | — | US | disclosed |
| US-9926320-B2 | Purine diones as Wnt pathway modulators | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2018-03-27 | — | — | US | disclosed |
| US-9926320-B2 | Purine diones as Wnt pathway modulators | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2018-03-27 | — | — | US | disclosed |
| US-9926320-B2 | Purine diones as Wnt pathway modulators | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2018-03-27 | — | — | US | disclosed |
| US-20170334912-A1 | Purine Diones As Wnt Pathway Modulators | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2017-11-23 | — | — | US | disclosed |
| US-20170334912-A1 | Purine Diones As Wnt Pathway Modulators | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2017-11-23 | — | — | US | disclosed |
| US-20170334912-A1 | Purine Diones As Wnt Pathway Modulators | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2017-11-23 | — | — | US | disclosed |
| US-20160090386-A1 | Purine Diones As Wnt Pathway Modulators | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2016-03-31 | — | — | US | disclosed |
| US-20160090386-A1 | Purine Diones As Wnt Pathway Modulators | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2016-03-31 | — | — | US | disclosed |
| US-20160090386-A1 | Purine Diones As Wnt Pathway Modulators | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2016-03-31 | — | — | US | disclosed |
| EP-2999699-A1 | PURINE DIONES AS WNT PATHWAY MODULATORS | Agency For Science, Technology And Research (SG) | 2016-03-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160090386-A1 | Purine Diones As Wnt Pathway Modulators | WNT1, WNT3A, CTNNB1 | ADORA2B 16/4885TNF 4534/4885SMN1; SMN2 4828/4885 |
| US-20170334912-A1 | Purine Diones As Wnt Pathway Modulators | WNT1, WNT3A, CTNNB1 | ADORA2B 16/4885TNF 4534/4885SMN1; SMN2 4828/4885 |
| US-11555037-B2 | Purine diones as Wnt pathway modulators | WNT1, WNT3A, WNT3 | ADORA2B 19/4885TNF 4540/4885SMN1; SMN2 4771/4885 |
| US-20220202821-A1 | SMALL MOLECULE PARG INHIBITORS AND METHODS OF USE THEREOF | PARG, PARP15, PLG | ADORA2B 2231/4885TNF 4881/4885SMN1; SMN2 4491/4885 |
| US-20230174533-A1 | PURINE DIONES AS WNT PATHWAY MODULATORS | WNT1, WNT3A, WNT3 | ADORA2B 19/4885TNF 4540/4885SMN1; SMN2 4771/4885 |
| US-10844063-B2 | Purine diones as Wnt pathway modulators | WNT1, WNT3A, CTNNB1 | ADORA2B 16/4885TNF 4534/4885SMN1; SMN2 4828/4885 |
| US-20210155623-A1 | PURINE DIONES AS WNT PATHWAY MODULATORS | WNT1, WNT3A, WNT3 | ADORA2B 19/4885TNF 4540/4885SMN1; SMN2 4771/4885 |
| US-12559495-B2 | Purine diones as Wnt pathway modulators | WNT1, CTNND1, WNT3A | ADORA2B 27/4885TNF 4747/4885SMN1; SMN2 3793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.